Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-155-5p ABCC4 -0.39 0.78945 -0.02 0.977 miRNAWalker2 validate -0.22 0.00218 NA
2 hsa-miR-155-5p ABL2 -0.39 0.78945 0.09 0.91468 mirMAP -0.11 0.00074 NA
3 hsa-miR-155-5p ACSL6 -0.39 0.78945 1.05 0.17112 mirMAP -0.95 1.0E-5 NA
4 hsa-miR-155-5p ADD3 -0.39 0.78945 0.14 0.91713 MirTarget; miRNATAP -0.13 0.00221 NA
5 hsa-miR-155-5p AGTR1 -0.39 0.78945 0.22 0.75375 miRNAWalker2 validate; miRTarBase -0.58 0.00073 22525818 MicroRNA-155 miR-155 is one of the micro RNAs miRNA most consistently involved in neoplastic diseases and it is known to repress the angiotensin II type 1 receptor AGTR1; The aim of the present study was to evaluate the expressions of miR-155 and AGTR1 and to clarify the potential efficacy of anti-miR-155 alone and in combination with AGTR1 blocker losartan in endometrial cancers; Expressions of miR-155 and AGTR1 were evaluated using real-time PCR and immunohistochemistry; miR-155 was over-expressed and AGTR1 was underexpressed in endometrial carcinoma tissues; We checked that abolishing the function of miR-155 and AGTR1 by anti-miR-155 or losartan inhibited cell survival of endometrial carcinoma cells respectively and furthermore combined treatment showed synergistic effects; In this study we characterized the expressions of miR-155 and AGTR1 in endometrial tissues; The combined treatment with anti-miR-155 and losartan has a synergistic antiproliferative effect and an improved understanding is required to clarify whether miR-155 and AGTR1 can be used as a novel therapeutic target in endometrial cancer
6 hsa-miR-155-5p ALDH5A1 -0.39 0.78945 0.04 0.96231 miRNAWalker2 validate -0.13 0.01007 NA
7 hsa-miR-155-5p AMIGO2 -0.39 0.78945 0.19 0.80365 miRNAWalker2 validate -0.21 0.01429 NA
8 hsa-miR-155-5p ANKH -0.39 0.78945 0.21 0.86724 mirMAP -0.33 0 NA
9 hsa-miR-155-5p ARHGAP18 -0.39 0.78945 0.08 0.94122 MirTarget -0.14 0.00064 NA
10 hsa-miR-155-5p ARL15 -0.39 0.78945 0.33 0.62789 miRNAWalker2 validate; miRNATAP -0.15 0.00054 NA
11 hsa-miR-155-5p ARMC2 -0.39 0.78945 -0.09 0.75269 miRNAWalker2 validate -0.22 0.00128 NA
12 hsa-miR-155-5p ASNS -0.39 0.78945 0.38 0.71317 miRNAWalker2 validate -0.16 0.00517 NA
13 hsa-miR-155-5p ATP6V1H -0.39 0.78945 0.02 0.98634 miRNAWalker2 validate -0.13 0.00011 NA
14 hsa-miR-155-5p ATRNL1 -0.39 0.78945 0.29 0.66607 MirTarget; mirMAP -0.47 0.00111 NA
15 hsa-miR-155-5p BCORL1 -0.39 0.78945 0.08 0.92003 MirTarget -0.1 0.01555 NA
16 hsa-miR-155-5p BRPF3 -0.39 0.78945 0.07 0.95006 miRNAWalker2 validate; miRTarBase -0.17 0 NA
17 hsa-miR-155-5p BRWD3 -0.39 0.78945 0.13 0.84771 miRNATAP -0.19 0.00012 NA
18 hsa-miR-155-5p CAB39L -0.39 0.78945 0.42 0.57664 miRNAWalker2 validate -0.57 0 NA
19 hsa-miR-155-5p CACNB4 -0.39 0.78945 0.22 0.59018 mirMAP; miRNATAP -0.32 0.00255 NA
20 hsa-miR-155-5p CADM2 -0.39 0.78945 0.76 0.4386 mirMAP -0.27 0.04245 NA
21 hsa-miR-155-5p CARS2 -0.39 0.78945 0.13 0.90307 miRNAWalker2 validate -0.1 0.01453 NA
22 hsa-miR-155-5p CAT -0.39 0.78945 0.09 0.94026 miRNAWalker2 validate -0.13 0.00087 NA
23 hsa-miR-155-5p CDH13 -0.39 0.78945 0.11 0.87193 miRNAWalker2 validate -0.33 0 NA
24 hsa-miR-155-5p CDH6 -0.39 0.78945 0.2 0.56314 miRNAWalker2 validate -0.28 0.00012 NA
25 hsa-miR-155-5p CDX1 -0.39 0.78945 0.02 0.99063 MirTarget -0.21 0.0203 NA
26 hsa-miR-155-5p CEP68 -0.39 0.78945 0.01 0.98851 MirTarget -0.2 0 NA
27 hsa-miR-155-5p CFL2 -0.39 0.78945 -0.06 0.92086 miRNAWalker2 validate -0.13 0.0473 NA
28 hsa-miR-155-5p CHD9 -0.39 0.78945 -0.03 0.975 miRNAWalker2 validate -0.1 0.00688 NA
29 hsa-miR-155-5p CLDN1 -0.39 0.78945 0.5 0.67614 miRNAWalker2 validate; miRTarBase -0.24 0.00592 23523916; 23588589 MicroRNA 155 is a novel suppressor of ovarian cancer initiating cells that targets CLDN1; Here we show that the downregulation of miR-155 in OCICs correlates with CLDN1 overexpression and the suppression of OCIC invasion; Luciferase assays indicate that miR-155 targets CLDN1 mRNA on the 3' UTR; Thus overexpression of miR-155 may prevent tumorigenesis in human ovarian cancer through downregulation of CLDN1;Upregulation of microRNA 155 promotes the migration and invasion of colorectal cancer cells through the regulation of claudin 1 expression; Furthermore the overexpression of miR-155 upregulated claudin-1 expression; Thus our data suggest that miR-155 plays an important role in promoting CRC cell migration and invasion at least in part through the regulation of claudin-1 expression and controlling metastasis in CRC
30 hsa-miR-155-5p CLIC4 -0.39 0.78945 0.22 0.85599 miRNAWalker2 validate -0.2 0.00081 NA
31 hsa-miR-155-5p CNTN3 -0.39 0.78945 1 0.10009 MirTarget -0.38 0.02319 NA
32 hsa-miR-155-5p COBLL1 -0.39 0.78945 0.15 0.86329 mirMAP -0.24 0 NA
33 hsa-miR-155-5p CSE1L -0.39 0.78945 0.12 0.92857 miRNAWalker2 validate -0.13 0.00187 NA
34 hsa-miR-155-5p CTNNBL1 -0.39 0.78945 0.11 0.92164 miRNAWalker2 validate -0.14 0.0013 NA
35 hsa-miR-155-5p CUL4B -0.39 0.78945 0.14 0.89837 miRNAWalker2 validate -0.15 0 NA
36 hsa-miR-155-5p CUX1 -0.39 0.78945 0 0.9999 miRNAWalker2 validate -0.15 7.0E-5 NA
37 hsa-miR-155-5p DET1 -0.39 0.78945 0.03 0.94183 miRNAWalker2 validate; miRTarBase -0.11 0.00073 NA
38 hsa-miR-155-5p DIXDC1 -0.39 0.78945 -0.07 0.91444 MirTarget -0.14 0.00694 NA
39 hsa-miR-155-5p DMD -0.39 0.78945 0.06 0.92185 miRNAWalker2 validate -0.57 0 NA
40 hsa-miR-155-5p DYNC1I1 -0.39 0.78945 0.56 0.24386 MirTarget; miRNATAP -0.42 0.00094 NA
41 hsa-miR-155-5p EEF1A2 -0.39 0.78945 0.55 0.35456 miRNAWalker2 validate -0.35 0.03563 NA
42 hsa-miR-155-5p EIF3E -0.39 0.78945 0.19 0.9046 miRNAWalker2 validate -0.19 0 NA
43 hsa-miR-155-5p ELAVL2 -0.39 0.78945 1.49 0.03805 miRNATAP -0.82 1.0E-5 NA
44 hsa-miR-155-5p ETNK2 -0.39 0.78945 0.17 0.67035 miRNATAP -0.56 0 NA
45 hsa-miR-155-5p FAM105A -0.39 0.78945 0.26 0.81361 MirTarget -0.35 0 NA
46 hsa-miR-155-5p FNDC3B -0.39 0.78945 0.11 0.92577 miRNAWalker2 validate -0.11 0.00292 NA
47 hsa-miR-155-5p FOXO3 -0.39 0.78945 -0.25 0.82525 miRNAWalker2 validate; miRTarBase -0.14 0.00074 27596294; 25480585; 20371610; 26398931; 22027557; 27107135 MiR-155 targets 3´UTR region of multiple components of the pro-oncogenic signaling cascades including FOXO3a tumor suppressor and RUNX2 transcription factor regulating metastatic potential in BC;The effect of miRNA155 on FOXO3a expression was examined by Western blotting; FOXO3a was found to be a possible target of miRNA155 as suggested by Targetscan website;MicroRNA 155 regulates cell survival growth and chemosensitivity by targeting FOXO3a in breast cancer; In this study we demonstrate the critical role of miR-155 in regulation of cell survival and chemosensitivity through down-regulation of FOXO3a in breast cancer; Further we identified FOXO3a as a direct target of miR-155; Sustained overexpression of miR-155 resulted in repression of FOXO3a protein without changing mRNA levels and knockdown of miR-155 increases FOXO3a; Finally inverse correlation between miR-155 and FOXO3a levels were observed in a panel of breast cancer cell lines and tumors; In conclusion our study reveals a molecular link between miR-155 and FOXO3a and presents evidence that miR-155 is a critical therapeutic target in breast cancer;In contrast downregulation of miR-155-5p increased sensitivity to bufalin and upregulated the expression of FOXO3A;Here we show that hypoxic conditions induce miR-155 expression in lung cancer cells and trigger a corresponding decrease in a validated target FOXO3A;Our results further revealed that forkhead box O3a FoxO3a was a miR-155 target in the heart; And miR-155 directly repressed FoxO3a whose expression was mitigated in miR-155 agomir and mimic treatment in vivo and in vitro
48 hsa-miR-155-5p FOXP4 -0.39 0.78945 -0.06 0.96165 mirMAP -0.19 0 NA
49 hsa-miR-155-5p FRYL -0.39 0.78945 -0.11 0.92898 miRNATAP -0.16 0.00041 NA
50 hsa-miR-155-5p FSD1L -0.39 0.78945 0.19 0.70683 mirMAP -0.18 0.00574 NA
51 hsa-miR-155-5p GABRB2 -0.39 0.78945 0.87 0.22364 mirMAP -0.58 0.003 NA
52 hsa-miR-155-5p GFPT1 -0.39 0.78945 -0.09 0.95113 mirMAP -0.11 0.00998 NA
53 hsa-miR-155-5p GLB1 -0.39 0.78945 0.06 0.96298 miRNAWalker2 validate -0.16 0 NA
54 hsa-miR-155-5p GNAS -0.39 0.78945 -0.08 0.96312 miRNAWalker2 validate; MirTarget -0.14 0.00083 NA
55 hsa-miR-155-5p GPM6B -0.39 0.78945 -0.02 0.94382 miRNAWalker2 validate; MirTarget -0.26 0.00565 NA
56 hsa-miR-155-5p GRIP1 -0.39 0.78945 0.49 0.20748 miRNATAP -0.47 3.0E-5 NA
57 hsa-miR-155-5p GSK3B -0.39 0.78945 0.06 0.95674 miRNAWalker2 validate; miRNATAP -0.1 0 NA
58 hsa-miR-155-5p GYG1 -0.39 0.78945 0.11 0.91181 MirTarget -0.12 3.0E-5 NA
59 hsa-miR-155-5p H3F3A -0.39 0.78945 0.06 0.96489 MirTarget; miRNATAP -0.11 0.00259 NA
60 hsa-miR-155-5p HBP1 -0.39 0.78945 0.01 0.99281 miRNAWalker2 validate; MirTarget; miRNATAP -0.1 0.00108 25666090 miR 155 promotes the growth of osteosarcoma in a HBP1 dependent mechanism; HMG-box transcription factor 1 HBP1 a strong Wnt pathway suppressor was found to be a target of miR-155; Restoration of HBP1 abolished the effect of miR-155 on OS cells
61 hsa-miR-155-5p HDAC2 -0.39 0.78945 -0.02 0.98555 mirMAP -0.11 0.00036 21946536 Mechanistically we found that BRCA1 epigenetically represses miR-155 expression via its association with HDAC2 which deacetylates histones H2A and H3 on the miR-155 promoter
62 hsa-miR-155-5p HSD17B12 -0.39 0.78945 0.05 0.97042 miRNAWalker2 validate -0.11 0.02313 NA
63 hsa-miR-155-5p HSDL1 -0.39 0.78945 0.16 0.84161 miRNAWalker2 validate -0.15 0 NA
64 hsa-miR-155-5p HUNK -0.39 0.78945 0.4 0.65764 mirMAP -0.4 0.00396 NA
65 hsa-miR-155-5p IGDCC4 -0.39 0.78945 -0.14 0.72951 MirTarget -0.17 0.03868 NA
66 hsa-miR-155-5p IGF1R -0.39 0.78945 -0.02 0.98494 mirMAP -0.16 0.00074 NA
67 hsa-miR-155-5p IL17RD -0.39 0.78945 0.03 0.96742 mirMAP -0.4 1.0E-5 NA
68 hsa-miR-155-5p IRF2BP2 -0.39 0.78945 0.08 0.95705 MirTarget; miRNATAP -0.17 0 NA
69 hsa-miR-155-5p JARID2 -0.39 0.78945 0.08 0.92709 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.1 0.00358 23185331 We furthermore identify Jarid2 a component of Polycomb repressive complex 2 as a novel validated target of miR-K12-11 and confirm its downregulation in miR-K12-11 as well as miR-155 expressing bone marrow cells
70 hsa-miR-155-5p JUN -0.39 0.78945 -0.2 0.89168 miRNAWalker2 validate; miRTarBase -0.14 0.01386 23693020 In the present study we demonstrated for the first time that activation of RAGE by S100P regulates oncogenic microRNA-155 miR-155 expression through Activator Protein-1 AP-1 stimulation in colon cancer cells
71 hsa-miR-155-5p KANK2 -0.39 0.78945 -0.08 0.93397 miRNAWalker2 validate -0.16 0.00332 NA
72 hsa-miR-155-5p KDELC1 -0.39 0.78945 0.38 0.43569 miRNAWalker2 validate -0.14 0.00777 NA
73 hsa-miR-155-5p KDM5B -0.39 0.78945 -0.05 0.96259 MirTarget -0.12 0.00435 NA
74 hsa-miR-155-5p KRT80 -0.39 0.78945 0.34 0.71365 miRNAWalker2 validate -0.19 0.02139 NA
75 hsa-miR-155-5p LCA5 -0.39 0.78945 0.04 0.88834 MirTarget -0.17 0.00743 NA
76 hsa-miR-155-5p LEPROT -0.39 0.78945 0.06 0.93963 mirMAP -0.11 0.02022 NA
77 hsa-miR-155-5p LNX2 -0.39 0.78945 0.27 0.78712 miRNAWalker2 validate -0.22 0 NA
78 hsa-miR-155-5p LONRF2 -0.39 0.78945 0.07 0.92207 mirMAP -0.41 0.01981 NA
79 hsa-miR-155-5p LPP -0.39 0.78945 -0.16 0.81235 mirMAP; miRNATAP -0.12 0.02933 NA
80 hsa-miR-155-5p MAP4K3 -0.39 0.78945 0.02 0.97838 MirTarget -0.11 0.00021 NA
81 hsa-miR-155-5p MAVS -0.39 0.78945 0.04 0.9738 miRNAWalker2 validate -0.1 0.02041 NA
82 hsa-miR-155-5p MBLAC2 -0.39 0.78945 0.23 0.68929 miRNAWalker2 validate -0.12 0.00202 NA
83 hsa-miR-155-5p MCAM -0.39 0.78945 0.12 0.91586 miRNAWalker2 validate -0.16 0.00586 NA
84 hsa-miR-155-5p MEST -0.39 0.78945 -0.03 0.98005 miRNAWalker2 validate -0.19 3.0E-5 NA
85 hsa-miR-155-5p MLH1 -0.39 0.78945 -0.01 0.99462 miRNAWalker2 validate; miRTarBase -0.23 0.00447 23715647; 21738581 MLH1 as a direct target of MiR 155 and a potential predictor of favorable prognosis in pancreatic cancer; The regulation of Mut L homologue 1 MLH1 expression by microRNA miR-155 and its prognostic significance in pancreatic cancer PC remain to be elucidated; Then luciferase activity was detected after miR-155 mimics and pRL-TK plasmids containing wild-type and mutant 3'UTRs of MLH1 mRNA were co-transfected; Transfection of miR-155 mimics and inhibitor led to reversely altered protein expressions of miR-155 and MLH1 whereas the corresponding mRNA expressions were similar; MLH1 might serve as a direct target of miR-155 and a potential prognosis predictor in PC;Predicted target mRNAs FGFR1 miR-10 and MLH1 miR-155 were found downregulated
86 hsa-miR-155-5p MMP16 -0.39 0.78945 0.34 0.32953 mirMAP -0.27 0.00297 NA
87 hsa-miR-155-5p MPP2 -0.39 0.78945 0.24 0.35779 miRNAWalker2 validate -0.16 0.04703 NA
88 hsa-miR-155-5p MYO10 -0.39 0.78945 0.1 0.93611 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.23 0 NA
89 hsa-miR-155-5p MYO1D -0.39 0.78945 -0.06 0.96858 miRNAWalker2 validate; miRNATAP -0.16 0.00126 NA
90 hsa-miR-155-5p NES -0.39 0.78945 -0.04 0.96956 miRNAWalker2 validate -0.24 0.00076 NA
91 hsa-miR-155-5p NEU1 -0.39 0.78945 0.27 0.82358 miRNAWalker2 validate -0.22 6.0E-5 NA
92 hsa-miR-155-5p NFAT5 -0.39 0.78945 0.15 0.89465 mirMAP; miRNATAP -0.15 0.00026 NA
93 hsa-miR-155-5p NFIA -0.39 0.78945 0.02 0.98541 miRNATAP -0.12 0.01424 NA
94 hsa-miR-155-5p NGEF -0.39 0.78945 0.19 0.82192 miRNATAP -0.19 0.0021 NA
95 hsa-miR-155-5p NUPL2 -0.39 0.78945 0.07 0.93702 miRNAWalker2 validate -0.1 0.00474 NA
96 hsa-miR-155-5p OLFML3 -0.39 0.78945 0.23 0.76152 miRNATAP -0.27 0.00221 NA
97 hsa-miR-155-5p OPHN1 -0.39 0.78945 0 0.99392 mirMAP -0.1 0.01552 NA
98 hsa-miR-155-5p PACSIN3 -0.39 0.78945 -0.16 0.83198 miRNAWalker2 validate -0.24 0.01036 NA
99 hsa-miR-155-5p PANK1 -0.39 0.78945 -0.15 0.85501 miRNATAP -0.13 0.0164 NA
100 hsa-miR-155-5p PCMTD1 -0.39 0.78945 0.18 0.85692 mirMAP -0.19 1.0E-5 NA
101 hsa-miR-155-5p PCYOX1 -0.39 0.78945 0.02 0.98777 miRNAWalker2 validate -0.1 0.00034 NA
102 hsa-miR-155-5p PDE1A -0.39 0.78945 0.32 0.38299 mirMAP -0.28 0.00991 NA
103 hsa-miR-155-5p PDE3A -0.39 0.78945 -0.01 0.98665 miRNAWalker2 validate -0.42 0.00086 NA
104 hsa-miR-155-5p PEG3 -0.39 0.78945 0.17 0.62677 miRNATAP -0.25 0.01737 NA
105 hsa-miR-155-5p PFDN4 -0.39 0.78945 0.22 0.79662 miRNAWalker2 validate -0.19 0.00066 NA
106 hsa-miR-155-5p PGR -0.39 0.78945 0.13 0.74672 mirMAP -0.25 0.03036 20388420; 19454029; 23162645 It's indicated that the up-regulation of miR-155 expression was associated with advanced TNM clinical stage median 0.316 0.358 and 0.417 respectively for stage I II and III tumor P = 0.002 lymph node metastasis median 0.383 and 0.355 respectively for cases with positive and negative lymph nodes P = 0.034 higher proliferation index median 0.387 and 0.353 respectively for cases with high proliferation index Ki67 > 10% and low proliferation index Ki67 ≤ 10% P = 0.019 estrogen receptor-positive 0.367 and 0.318 respectively for cases with positive estrogen receptor and negative group P = 0.041 and progesterone receptor-positive 0.398 and 0.335 respectively for cases with positive progesterone receptor and negative group P = 0.029 in patients with breast cancer; The expression of miR-155 is up-regulated in primary breast cancer especially in patients with positive estrogen and progesterone receptor;While the expression of all three miRNAs was similar in samples from healthy women compared to those with breast cancer women with progesterone receptor PR p = 0.016 positive tumors had higher miR-155 expression than tumors that were negative for these receptors;miR 155 and miR 31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status; The expression levels of miR-155 but not miR-31 were inversely correlated with estrogen receptor ER and progesterone receptor PR expression ER r=-0.353 P=0.003; PR r=-0.357 P=0.003
107 hsa-miR-155-5p PHF14 -0.39 0.78945 0.1 0.91828 miRNAWalker2 validate -0.11 0.00037 NA
108 hsa-miR-155-5p PHGDH -0.39 0.78945 0.81 0.42989 miRNAWalker2 validate -0.44 7.0E-5 NA
109 hsa-miR-155-5p PLAG1 -0.39 0.78945 0.56 0.16053 miRNATAP -0.56 0 NA
110 hsa-miR-155-5p PLEKHA5 -0.39 0.78945 0.11 0.9059 miRNAWalker2 validate -0.14 5.0E-5 NA
111 hsa-miR-155-5p PNPLA4 -0.39 0.78945 -0.09 0.90319 miRNAWalker2 validate -0.17 0.03407 NA
112 hsa-miR-155-5p POU2F1 -0.39 0.78945 -0.13 0.68879 mirMAP -0.12 0.0256 NA
113 hsa-miR-155-5p PRKG1 -0.39 0.78945 0.27 0.46388 miRNATAP -0.41 4.0E-5 NA
114 hsa-miR-155-5p PROX1 -0.39 0.78945 -0.09 0.89082 miRNATAP -0.41 2.0E-5 NA
115 hsa-miR-155-5p PTCHD1 -0.39 0.78945 -0.66 0.40025 mirMAP -0.36 0.02575 NA
116 hsa-miR-155-5p PUS7 -0.39 0.78945 -0.02 0.98149 miRNAWalker2 validate -0.11 0.01015 NA
117 hsa-miR-155-5p RAB11FIP2 -0.39 0.78945 0.16 0.82288 miRNAWalker2 validate; MirTarget; miRNATAP -0.21 0 NA
118 hsa-miR-155-5p RAB22A -0.39 0.78945 0.13 0.90978 mirMAP -0.11 0.00279 NA
119 hsa-miR-155-5p RAB2A -0.39 0.78945 -0.15 0.8876 miRNAWalker2 validate -0.11 0.00015 NA
120 hsa-miR-155-5p RAB6C -0.39 0.78945 0.23 0.46093 miRNAWalker2 validate -0.12 0.00131 NA
121 hsa-miR-155-5p RAP2A -0.39 0.78945 0.21 0.84247 mirMAP -0.12 0.00223 NA
122 hsa-miR-155-5p RAPGEF2 -0.39 0.78945 0.09 0.92335 miRNAWalker2 validate; MirTarget -0.1 0.00207 NA
123 hsa-miR-155-5p RAPGEF4 -0.39 0.78945 0.84 0.02124 miRNATAP -0.35 2.0E-5 NA
124 hsa-miR-155-5p RBP2 -0.39 0.78945 0.34 0.65414 MirTarget -0.83 0.00038 NA
125 hsa-miR-155-5p RCN2 -0.39 0.78945 0.09 0.93582 miRNAWalker2 validate; MirTarget -0.1 0.0032 NA
126 hsa-miR-155-5p REPS2 -0.39 0.78945 -0.31 0.72558 MirTarget; miRNATAP -0.2 0.00132 NA
127 hsa-miR-155-5p RHEB -0.39 0.78945 0.04 0.97071 miRNAWalker2 validate; miRNATAP -0.12 0.00028 NA
128 hsa-miR-155-5p RNF2 -0.39 0.78945 0.16 0.83872 miRNAWalker2 validate -0.12 0.00029 NA
129 hsa-miR-155-5p RPGRIP1L -0.39 0.78945 -0.17 0.76832 mirMAP -0.12 0.00396 NA
130 hsa-miR-155-5p RPL39 -0.39 0.78945 0.21 0.82074 miRNAWalker2 validate -0.19 0.00157 NA
131 hsa-miR-155-5p SALL1 -0.39 0.78945 -0.03 0.94731 miRNATAP -0.38 0.00214 NA
132 hsa-miR-155-5p SATB1 -0.39 0.78945 0.62 0.46209 MirTarget; miRNATAP -0.37 2.0E-5 NA
133 hsa-miR-155-5p SCAMP1 -0.39 0.78945 0.15 0.88139 miRNAWalker2 validate -0.1 0.001 NA
134 hsa-miR-155-5p SCML2 -0.39 0.78945 0.34 0.45254 mirMAP -0.29 0.01332 NA
135 hsa-miR-155-5p SCUBE2 -0.39 0.78945 0.24 0.57991 MirTarget -0.44 9.0E-5 NA
136 hsa-miR-155-5p SECISBP2 -0.39 0.78945 0.14 0.89354 miRNAWalker2 validate -0.1 0.0006 NA
137 hsa-miR-155-5p SEMA5A -0.39 0.78945 -0.02 0.98064 miRNATAP -0.42 0 NA
138 hsa-miR-155-5p SERPINA10 -0.39 0.78945 0.61 0.43294 MirTarget -1.43 0 NA
139 hsa-miR-155-5p SH3BP4 -0.39 0.78945 0 0.9995 miRNAWalker2 validate -0.16 9.0E-5 NA
140 hsa-miR-155-5p SIM2 -0.39 0.78945 0.29 0.67309 miRNATAP -0.23 0.02853 NA
141 hsa-miR-155-5p SLC13A3 -0.39 0.78945 0.73 0.26925 mirMAP -0.91 0 NA
142 hsa-miR-155-5p SLC25A36 -0.39 0.78945 0.16 0.87462 mirMAP -0.12 4.0E-5 NA
143 hsa-miR-155-5p SLC30A1 -0.39 0.78945 0.12 0.87083 miRNAWalker2 validate -0.1 0.00516 NA
144 hsa-miR-155-5p SLC35F5 -0.39 0.78945 0.03 0.97879 MirTarget -0.16 1.0E-5 NA
145 hsa-miR-155-5p SLC39A10 -0.39 0.78945 0.18 0.84429 miRNAWalker2 validate; miRNATAP -0.23 0 NA
146 hsa-miR-155-5p SLC7A1 -0.39 0.78945 0.27 0.83474 miRNAWalker2 validate -0.11 0.01326 NA
147 hsa-miR-155-5p SMAD9 -0.39 0.78945 -0.55 0.23355 mirMAP -0.61 0 NA
148 hsa-miR-155-5p SORL1 -0.39 0.78945 0.12 0.92844 miRNATAP -0.2 0.00048 NA
149 hsa-miR-155-5p SORT1 -0.39 0.78945 0.03 0.98121 MirTarget -0.16 0.00016 NA
150 hsa-miR-155-5p SOX11 -0.39 0.78945 0.41 0.30232 miRNATAP -0.34 0.00222 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
NumGOOverlapSizeP ValueAdj. P Value
1 NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY 32 1199 1.936e-07 0.0001799
2 REGULATORY REGION NUCLEIC ACID BINDING 23 818 5.198e-06 0.002415
NumGOOverlapSizeP ValueAdj. P Value

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa00250_Alanine._aspartate_and_glutamate_metabolism 3 32 0.003676 0.5257
2 hsa04662_B_cell_receptor_signaling_pathway 4 75 0.006214 0.5257
3 hsa04360_Axon_guidance 5 130 0.008982 0.5257
4 hsa00511_Other_glycan_degradation 2 17 0.01168 0.5257
5 hsa04916_Melanogenesis 4 101 0.01719 0.6187
6 hsa04660_T_cell_receptor_signaling_pathway 4 108 0.02141 0.6424
7 hsa04142_Lysosome 4 121 0.03083 0.6979
8 hsa04730_Long.term_depression 3 70 0.03102 0.6979
9 hsa04722_Neurotrophin_signaling_pathway 4 127 0.03588 0.7176
10 hsa04012_ErbB_signaling_pathway 3 87 0.05335 0.8223
11 hsa04914_Progesterone.mediated_oocyte_maturation 3 87 0.05335 0.8223
12 hsa00600_Sphingolipid_metabolism 2 40 0.05793 0.8223
13 hsa04310_Wnt_signaling_pathway 4 151 0.06059 0.8223
14 hsa04666_Fc_gamma_R.mediated_phagocytosis 3 95 0.06592 0.8223
15 hsa04962_Vasopressin.regulated_water_reabsorption 2 44 0.06853 0.8223
16 hsa04150_mTOR_signaling_pathway 2 52 0.09139 0.9586
17 hsa04742_Taste_transduction 2 52 0.09139 0.9586
18 hsa04340_Hedgehog_signaling_pathway 2 56 0.1035 0.9586
19 hsa04270_Vascular_smooth_muscle_contraction 3 116 0.1045 0.9586
20 hsa04670_Leukocyte_transendothelial_migration 3 117 0.1065 0.9586
21 hsa04110_Cell_cycle 3 128 0.1297 0.9867
22 hsa04510_Focal_adhesion 4 200 0.1321 0.9867
23 hsa04144_Endocytosis 4 203 0.1373 0.9867
24 hsa04910_Insulin_signaling_pathway 3 138 0.1522 0.9867
25 hsa04976_Bile_secretion 2 71 0.1524 0.9867
26 hsa04146_Peroxisome 2 79 0.18 1
27 hsa03013_RNA_transport 3 152 0.1855 1
28 hsa04970_Salivary_secretion 2 89 0.2154 1
29 hsa04540_Gap_junction 2 90 0.219 1
30 hsa04020_Calcium_signaling_pathway 3 177 0.2489 1
31 hsa04912_GnRH_signaling_pathway 2 101 0.2586 1
32 hsa04010_MAPK_signaling_pathway 4 268 0.2658 1
33 hsa04062_Chemokine_signaling_pathway 3 189 0.2804 1
34 hsa04114_Oocyte_meiosis 2 114 0.3055 1
35 hsa04650_Natural_killer_cell_mediated_cytotoxicity 2 136 0.3833 1
36 hsa04120_Ubiquitin_mediated_proteolysis 2 139 0.3937 1
37 hsa04390_Hippo_signaling_pathway 2 154 0.4441 1
38 hsa04151_PI3K_AKT_signaling_pathway 4 351 0.4477 1
39 hsa04145_Phagosome 2 156 0.4507 1
40 hsa00230_Purine_metabolism 2 162 0.4701 1
41 hsa04810_Regulation_of_actin_cytoskeleton 2 214 0.6198 1
42 hsa04014_Ras_signaling_pathway 2 236 0.6726 1

Quest ID: 0ac34e4a9e2f54684be47d57c2239854